Decoy Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Decoy Therapeutics Inc. (DCOY) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-31
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2021-03-31 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-03-31 was $7.82, a 34.45% decline year-over-year.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 10 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-21 | ||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-22 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-05 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2019-07-17 | ||||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 | ||||
| 2018-12-31 | $5.76 10-K · filed 2019-03-06 | ||||
| 2018-09-30 | $5.96 10-Q · filed 2018-11-05 | ||||
| 2018-06-30 | $6.17 10-Q · filed 2018-08-01 | ||||
| 2018-03-31 | $7.82 10-Q · filed 2018-05-02 | ||||
| 2017-12-31 | $8.87 10-K · filed 2018-03-07 | ||||
| 2017-09-30 | $9.37 10-Q · filed 2017-11-06 | ||||
| 2017-06-30 | $9.81 10-Q · filed 2017-08-02 | ||||
| 2017-03-31 | $11.93 10-Q · filed 2017-05-03 | ||||
| 2016-12-31 | $9.86 10-K · filed 2017-03-08 | ||||
| 2016-09-30 | $11.99 10-Q · filed 2016-11-02 | ||||
| 2016-06-30 | $12.94 10-Q · filed 2016-08-03 | ||||
| 2016-03-31 | $11.32 10-Q · filed 2016-05-04 | ||||
| 2015-12-31 | $10.69 10-K · filed 2016-03-08 | ||||
| 2015-09-30 | $9.93 10-Q · filed 2015-11-04 | ||||
| 2015-06-30 | $9.48 10-Q · filed 2015-08-05 | ||||
| 2015-03-31 | $10.79 10-Q · filed 2015-05-06 | ||||
| 2014-12-31 | $1.14 10-K · filed 2015-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |